Your browser doesn't support javascript.
loading
TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study.
van de Bovenkamp, A A; Bakermans, A J; Allaart, C P; Nederveen, A J; Kok, W E M; van Rossum, A C; Handoko, M L.
Afiliação
  • van de Bovenkamp AA; Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
  • Bakermans AJ; Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Allaart CP; Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
  • Nederveen AJ; Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Kok WEM; Department of Clinical and Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Heart Center, Amsterdam, The Netherlands.
  • van Rossum AC; Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
  • Handoko ML; Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. ml.handoko@amsterdamumc.nl.
Neth Heart J ; 28(6): 312-319, 2020 Jun.
Article em En | MEDLINE | ID: mdl-32162204

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Aspecto: Patient_preference Idioma: En Revista: Neth Heart J Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Aspecto: Patient_preference Idioma: En Revista: Neth Heart J Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda
...